Treatment of Prostate Cancer by TNM Stage
For localized prostate cancer (T1-T2), treatment selection depends on risk stratification and life expectancy, with active surveillance for low-risk disease, radical prostatectomy or radiation therapy (≥74-78 Gy) for intermediate-to-high risk disease; for locally advanced disease (T3-T4), radiation therapy with 3 years of androgen deprivation therapy is the standard; for metastatic disease (N1 or M1), ADT combined with either abiraterone, enzalutamide, apalutamide, or docetaxel is recommended over ADT alone. 1, 2
Localized Disease (T1-T2, N0, M0)
Low-Risk Disease
- Active surveillance is the preferred approach for men with low-risk prostate cancer and life expectancy >10 years 1
- Biopsy progression indicates need for active intervention; PSA doubling time role remains controversial 3
- Individualized follow-up based on PSA and disease-specific history 3
Intermediate-to-High Risk Disease (Life Expectancy >10 Years)
Active treatment options include:
Radical Prostatectomy:
- Nerve-sparing approach is preferred for organ-confined disease 3
- Superior to watchful waiting in prospective randomized trials 3
- Neoadjuvant ADT provides no outcome improvement 3
Radiation Therapy:
- Minimum 74 Gy for low-risk disease 3
- 78 Gy for intermediate or high-risk disease 3
- Can be delivered externally or via brachytherapy 3
Very Low-Risk or Limited Life Expectancy
- Watchful waiting is appropriate for locally advanced disease not requiring immediate intervention 3
- Equivalent oncologic efficacy to ADT in this population 3
Locally Advanced Disease (T3-T4, N0, M0)
Radiation therapy (78 Gy) plus ADT for 3 years is the treatment of choice, resulting in superior disease-specific and overall survival 3
For T4a disease with bladder invasion in selected patients, radical cystoprostatectomy followed by immediate ADT may be considered for excellent local control, though this remains debatable 4
Node-Positive, Non-Metastatic Disease (N1, M0)
ADT plus abiraterone and prednisolone should be considered over castration monotherapy due to failure-free survival benefit 2
- Radiation therapy to the primary is mandated for newly diagnosed node-negative disease and encouraged for node-positive disease in this setting 2
- 5-year overall survival with ADT: 76.0%; cancer-specific survival: 83.2% 5
Metastatic Hormone-Sensitive Prostate Cancer (M1)
ADT monotherapy is no longer the standard of care. Combination therapy with ADT plus one of the following agents significantly improves outcomes 2:
First-Line Options (All Strong Recommendations):
ADT + Abiraterone (1000 mg daily) + Prednisone (5 mg twice daily):
- Evidence quality: high 2
- Benefits across all disease volumes
ADT + Enzalutamide (160 mg daily):
- Evidence quality: high 2
- Significantly reduces radiographic disease progression or death 2
- Long-term benefits in docetaxel-pretreated patients still being confirmed 2
ADT + Apalutamide (240 mg daily):
- Evidence quality: high 2
- At 22.7 months, significantly longer radiographic progression-free survival and overall survival 2
- Effect on radiographic PFS favorable for most subgroups except previous docetaxel use (favored but not statistically significant) 2
ADT + Docetaxel:
- Established option, particularly for high-volume disease 2
Disease Volume Considerations:
- Low-volume metastatic disease: Local radiotherapy to the prostate should be considered in addition to systemic therapy 6
- 5-year survival by stage: M1a (non-regional lymph nodes): 57.5% OS; M1b (bone): 54.0% OS; M1c (other sites): 40.0% OS 5
Important Caveat:
Combined androgen blockade provides better overall survival than non-CAB treatments at any tumor stage 5. Patient discussions should include cost considerations and, for newer agents, the evolving long-term benefit data 2.
Biochemical Recurrence After Local Therapy
PSMA PET/CT has become increasingly important for staging biochemical recurrence 6
Early salvage radiotherapy after radical prostatectomy:
- As effective as adjuvant radiotherapy 6
- Should be combined with androgen deprivation in selected patients 6
Castration-Resistant Prostate Cancer (CRPC)
For nonmetastatic and metastatic CRPC, multiple new treatment options have emerged 6, though specific stage-wise recommendations require consideration of prior treatments, disease burden, and molecular characteristics 7.
Key Staging Considerations:
The 2017 TNM classification (8th edition) should be used, though imaging advances (MRI, PSMA PET/CT) are causing stage shifts 1. The molecular imaging TNM (miTNM) classification using PSMA PET/CT likely indicates better prognosis than traditional staging due to higher sensitivity 1.